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ABSTRACT
Methods: 5-FU and Cel combination were loaded in Eudragit coated chitosan (CH) microspheres (MSs) and characterized.
Results: The average particle size of the MSs was in the range of 2.7±0.9µm to 4.8±1.1µm. A substantial drug encapsulation efficiency of 71.30±2.3%  as 
obtained for 5-FU as compared to 35.20±1.9% of Cel in the tailored microparticles. The drug loading capacity of 6.5 mg/10 mg and 2.3 mg/10 mg was 
obtained for 5-FU and Cel, respectively. By Eudragit S 100 (Ed) coating, significant pH-dependent release profile was achieved, and no drug release was 
observed in simulated gastric and intestinal fluids. The developed MSs exhibited the release of 92.1±2.9% of 5-FU in 8h whereas 18.9±0.7% Cel was 
found to be released from the developed MSs. The drug-loaded MSs exhibited appreciable potency against HT-29 cells with an IC50 value of 35.9 µM.
Conclusion: The results indicated that these microparticles are a promising vehicle for selectively targeting drugs to the colon in the chemotherapy 
of colon cancer.
Keywords: 5-Fluorouracil, Celecoxib, Chitosan, Eudragit coating, Colon targeting, Cytotoxicity.
INTRODUCTION
Colorectal cancer (CRC) is the third leading cause of death in all kinds 
of cancer after lung and liver cancer followed by stomach and breast 
cancer [1]. The occurrence of CRC varies globally, and more number of 
cases is reported in countries such as North America, Japan, Australia, 
Western Europe, and New Zealand [2]. Very few cases of CRC are 
connected with genetic disorders [3,4].
5-Fluorouracil (5-FU), a synthetic pyrimidine antimetabolite is the 
most effective and first line drug for the treatment of CRC [5]. Despite 
its efficacy against CRC, 5-FU suffers from several drawbacks including a 
short biological half-life, invariable oral bioavailability, the requirement 
of multiple dosages for successful chemotherapy, and gradual increase 
in the drug resistance [6]. This chemotherapeutic agent is administered 
as continuous intravenous infusion which causes side effects in non-
targeted organs also.
5-FU also has cardiotoxic potential including angina pectoris, myocardial 
infarction, arrhythmias, heart failure, and cardiogenic shock [7]. 5-FU 
also reduces the heart pump capacity which leads to heart insufficiency 
due to scattered necrosis with loss of cardiomyocytes [8].
Various studies have demonstrated the role of nonsteroidal anti-
inflammatory drugs in decreased risk of CRC [9]. Epidemiologic, clinical 
and laboratory-based investigations distinguished cyclooxygenase-2 
(COX-2) as a potential molecular target, responsible for the production of 
PGs which stimulates cancer-associated angiogenesis [4]. Furthermore, 
it is also documented that the COX-2 levels are increased in 85% of 
human colorectal adenocarcinomas [10,11]. Therefore, selective COX-
2 inhibitors like celecoxib (Cel) hold a very good application prospect 
for the prevention and treatment of colon cancer [6]. A study was 
conducted on the role of Cel in familial adenomatous polyposis (FAP) 
which shows twice daily dose of 400 mg of Cel significantly reduced the 
number and size of colorectal polyps [12]. Cel is approved by US Food 
and Drug Administration in the patients of FAP as add-on therapy to 
inhibit the growth of adenomatous polyps [13,14].
Studies conducted in the past revealed the synergistic effect of Cel 
when combined with 5-FU to retard the growth of colon tumor. Induced 
apoptosis of colon tumor cells and considerable tumor regression along 
with increased COX-2 inhibition was manifested in a subcutaneous 
implantation tumor model of HT-29 colon cancer cell line. Treated 
group of nude mice exhibited induced expression of cytochrome C, 
caspase-3, and caspase-9 indicative of apoptosis [6]. Chemosensitivity 
of 5-FU resistant cells was improved when exposed to the combination 
of 5-FU and Cel [11].
Various approaches have been developed for site-specific drug delivery 
of anticancer molecule in the colon, which may lead to a substantial 
decrease in the dose and dose-related side effects. Techniques such 
as pH-dependent systems, pressure dependent formulations, time-
dependent approaches, and bacteria dependent systems are reported 
in literature [15,16].
Chitosan (CH), a cationic polysaccharide is a natural polymer obtained 
by treating chitin with sodium hydroxide and gained tremendous 
importance in the field of colon delivery. Due to its unique properties 
such as biodegradability, biocompatibility, and low toxicity, it has 
attracted the attention of formulation scientists for the fabrication of 
colon targeted tablets, beads, microparticles, and nanoparticles enable 
them to release the drug in colonic milieu [17,18]. It has been used 
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Research Article
Objective: 5-Fluorouracil (5-FU) and celecoxib (Cel) combination offered additive effect in the treatment of colon cancer. However, physicochemical and 
biopharmaceutical attributes of both drugs deliver suboptimal concentration at the site of action.
The objective of the current study is the development of a microparticulate drug delivery system loaded with a combination of 5-FU and Cel to 
achieve prolonged drug delivery in colon cancer.
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successfully in the delivery of drugs such as valdecoxib, 5-FU, curcumin, 
icariin, and vancomycin [19-24].
Ed, a pH-sensitive polymer protects the loss of drug in the upper 
gastrointestinal tract and subsequently results in the successful delivery 
of drugs in the colon only. Ed coating is already been used by formulation 
scientist for the successful delivery of 5-FU and valdecoxib [19,20].
Therefore, in the present investigation, a combination of 5-FU and Cel 
was loaded in Ed coated CH-microspheres (MSs) as a novel approach 
to deliver the “cocktail of therapeutic moities” for the management 
of colon cancer. 5-FU and Cel combination loaded Ed coated CH-MSs 
were prepared by two methods, namely emulsion polymerization and 
nonaqueous solvent evaporation methods for investigating the effect 
on particle size and entrapment efficiency (EE). Both types of MSs 
were characterized with particle size analyzer, transmission electron 
microscope (TEM), EE, drug loading capacity, Fourier transform 
infrared spectroscopy (FTIR), X-ray diffraction (XRD), and differential 
scanning calorimetry (DSC). The optimized formulation was further 
characterized for in vitro drug release and cytotoxicity analysis against 




5-FU was purchased from CDH-Laboratory Chemicals India, whereas Cel 
was obtained as a gift sample from Cadila Pharmaceutical, Ahmadabad, 
India. HT-29 human colon cancer cell lines were purchased from NCS, 
Pune, India. CH and Ed were procured from HiMedia Laboratories, 
Mumbai, India. Glutaraldehyde (GA) and span 80 were purchased from 
Loba Chemie, Mumbai, India. Acetonitrile and water (high-performance 
liquid chromatography [HPLC] grade) were purchased from Fisher 
Scientific, Mumbai, India. All other reagents and chemicals were of 
analytical grade.
Cell culture and reagents
Human colon cancer cell lines (HT-29) were maintained at 37°C in 
CO2 (5%), and air (95%) with Dulbecco’s modified eagle medium 
(DMEM) enriched with fetal bovine serum (10%).
Methods
Preparation of drug loaded CH-MSs by an emulsion polymerization 
method
Emulsion polymerization method was employed for the development 
of CH-MSs loaded with 5-FU and Cel. In brief, a weighed quantity of 
CH (200 mg) was dissolved in 15 ml of 5% acetic acid, and 475 mg of 
5-FU and 200 mg of Cel was added to it. This drug-polymer dispersion 
was added dropwise with the help of hypodermic syringe in a 150 ml 
liquid paraffin (75 ml light liquid paraffin +75 ml heavy liquid paraffin) 
containing 1% w/w span 80 and it was stirred with the help of 
mechanical stirrer for 1 h at 2500 revolutions per minute (RPM) and 
a temperature of 70°C. After 1 h a saturated solution of cross-linking 
agent (10 ml GA: 30 ml toluene) was added and stirred continuously 
until 2 h at 55°C. Suspension of cross-linked CH-MSs in paraffin oil thus 
obtained was allowed to stand for 20 min to let the MSs settle down 
under gravity. MSs were separated by filtration and washed several 
times with n-hexane to remove traces of the oil and finally with water 
to remove excess of GA. The MSs were dried at room temperature for 
24 h and stored in desiccators [25].
Preparation of drug loaded CH-MSs by nonaqueous solvent 
evaporation method
Nonaqueous solvent evaporation method was also used to prepare 
CH-MSs. In a nutshell, a weighed quantity of CH (250 mg) was dissolved 
in 10 ml of acetone, and the combination of 5-FU (475 mg) and Cel 
(200 mg) was added to it. The prepared slurry was added into 30 ml 
of liquid paraffin. The mixture was stirred with the help of mechanical 
stirrer at the speed of 1200 RPM for 4 h at room temperature. MSs were 
obtained after evaporation of the solvent and further washed repeatedly 
with petroleum ether to remove traces of oil and acetone. The washed 
MSs were stored at room temperature for 3 h and subsequently stored 
in desiccators [26].
Coating of drug loaded CH-MSs by an emulsification-solvent 
evaporation method
Emulsification-solvent evaporation method was employed for the coating 
of 5-FU and Cel loaded CH-MSs with Ed. The prepared drug-loaded CH-
MSs (100 mg) were coated with 10 ml of 10% w/v ethanolic solution 
of Ed. Light liquid paraffin (70 ml) and span 80 (1% v/v) was added 
for emulsification followed by stirring for 3 h at 1000 RPM at room 
temperature for removal of the solvent by evaporation. The prepared drug-
loaded Ed-CH-5-FU-Cel-MSs were filtered and washed with n-hexane and 
dried at room temperature and stored in desiccators [21,27].
Characterization of drug loaded MSs
FTIR spectroscopy
FTIR spectrum of 5-FU, Cel, physical mixture of 5-FU and Cel (5-FU-
Cel-PM), Physical mixture of CH and Ed with both the drug molecules 
under investigation (Ed-CH-5-FU-Cel–PM) and Ed-CH-5-FU-Cel-MSs 
was recorded using infrared spectrophotometer (Alpha-E) utilizing KBr 
disc method (2 mg sample in 200 mg KBr). The scanning range selected 
for the study was 4000–400 cm−1 at a resolution of 4 cm−1.
DSC
DSC thermograms were recorded for 5-FU-Cel-PM and Ed-CH-5-FU-
Cel-MSs using DSC (Mettler Toledo, 822e, Griefensee, Switzerland). 
All samples were hermetically sealed in crimped aluminum pan and 
subsequently heated at a temperature range of 30–300°C and cooling 
rate of 10°C/min in an inert environment of nitrogen gas.
Powder XRD (PXRD)
X-ray pattern of the selected samples was recorded using X-ray 
diffractometer (X’Pert PRO, Panalytical Company, Netherlands). Nickel 
filtered, CuKα radiations generated at a voltage of 60 kV and 50 mA 
current were employed for study at a scanning rate of 1°/min over the 
diffraction angle (2θ) range of 10–60°. PXRD diffractograms of 5-FU, 
Cel, and Ed-CH-5-FU-Cel-MSs were recorded and analyzed.
Particle size analysis
The mean particle size distribution of prepared Ed-Ch-5FU-Cel-MSs 
was calculated by laser diffractometry using Mastersizer 2000, Melvern 
Instruments Ltd. for dry powder measurement. The accurately weighed 
MSs (20 mg) were dispersed in HPLC water and visualized for particle 
size distribution [28,29].
TEM
The shape and surface morphology of the developed Ed coated CH-MSs 
was investigated using TEM (FTI Tecnai F20). An aqueous suspension 
of MSs was drop cast onto a carbon coated grid which was then air dried 
at room temperature before loading into a microscope, maintained at a 
voltage of 80 kV.
Drug EE and drug loading capacity
Drug EE% of 5-FU and Cel in the developed MSs was determined using 
an HPLC method. For this purpose, precisely weighed (10 mg) of coated 
MSs were added into 10 ml of acetonitrile:water (50:50) mixture and 
subjected to centrifugation at 1500 RPM for 10 min. The resulting 
clear centrifuge (2 ml) was pipetted out and filtered through 0.45 µm 
membrane filter. 20 μL of this filtered solution was then injected into 
HPLC column and analyzed at 260 nm [28,29].
The percent drug EE and drug loading capacity were calculated using 
the following equations:
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EE (%)=Actual drug loading/Theoretical drug loading×100
DLC=Drug weight within the microspheres/weight of microspheres
In vitro drug release studies
Ed-CH-5FU-Cel-MSs were evaluated for in vitro drug release in pH 
progression medium at 37°C±0.5°C. The dissolution study was 
performed using the paddle method. Accurately weighed coated 
MSs (100 mg) were deliberately spread over the surface of 900 ml of 
dissolution medium. The content was rotated at 50 RPM. To compare 
the release of 5-FU and Cel under different GI transit condition, the pH 
of the dissolution medium was altered at different time intervals. The 
experiments were performed in an acidic buffer (pH 2.0) for 2 h, which 
simulates the condition of the fasted stomach. After that, the study was 
conducted in the phosphate buffer (pH 4.5) to simulate duodenum 
for 2 h followed by in phosphate buffer (pH 6.8), which simulates mid 
jejunum. Finally, drug release study was continued in phosphate buffer 
(pH 7.4) to simulate ileo-colonic conditions for the next 2 h. Sample 
(5 ml) was withdrawn at specific time intervals (after 5, 15, 30, and 
60 min for 1st h, afterward every hour till the end of the study) and 
replaced with fresh dissolution medium to mimic finite sink conditions. 
The samples were passed through a microfilter and analyzed by HPLC 
for estimation of drug release. The dissolution study was performed in 
triplicate [20,21,29,30].
In vitro cytotoxicity assay
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) 
assay, a standard colorimetry based assay was selected for the 
determination of cytotoxicity. HT-29 human colon cancer cell line was 
cultured in a 96 well microtiter plate. Briefly, HT-29 cells were implanted 
in 200 µL of the serum DMEM medium at a density of 5×103 cells per 
well. After the incubation period of 24 h, the medium was replaced with 
serum-free-DMEM. After 24 h, the HT 29 cells were exposed to 5-FU, 
Cel, 5-FU-Cel, Ed-CH-5-FU-Cel-MSs and blank MSs (Bl-MSs) equivalent 
to 10–70 µM of 5-FU and Cel for 72 h. At the end of the treatment, the 
medium was removed and the cells were treated with 0.5 mg/ml of 
MTT dye for 4 h at 37°C. The HT 29 cells were lysed and thus formed 
formazan crystals were dissolved in 100 µL of DMSO and quantified by 
ELISA reader at 570 nm and 630 nm. The experiments were performed 
in triplicate (n=3) [31-33].
RESULTS AND DISCUSSION
Preparation and characterization of MSs
Ed-CH-5-FU-Cel-MSs were prepared by emulsion polymerization 
method and characterized under a set of stringent parameters [25].
Characterization of MSs
FTIR spectroscopy
The results of the FTIR spectrum of 5-FU, Cel, 5-FU-Cel-PM, Ed-CH-
5-FU-Cel-PM and Ed-CH-5-FU-Cel-MSs are shown in Table 1. FTIR 
spectrum showed characteristic peak due to pure 5-FU at 1641 and 
1229 cm−1 correspond to the C=O and C-X, respectively. The spectrum 
of Cel showed a characteristic peak at 3331, 1345, and 1138 cm−1 due 
to N-H stretching and S=O stretching vibrations of sulfonamide. In 
5-FU-Cel-PM a slight shift was observed at 1226 and 1138 cm-1 from 
the original peaks of 5-FU and Cel, respectively. The spectrum of Ed-
CH-5-FU-Cel-MSs indicated that characteristic peaks of 5-FU, Cel, and 
Ed are present in the PM of drugs and excipients as well as in the 
drug-loaded MSs. However, broadening and decrease in peak intensity 
were observed in the spectrum of drug loaded MSs which indicated no 
chemical interaction between drug and polymer [21].
DSC
DSC thermograms of 5-FU-Cel-PM along with Ed-CH-5-FU-Cel-MSs 
are presented in Fig. 1. A sharp endothermic peak at 162.02°C was 
observed for 5-FU, close to its investigated melting point (158°C). On 
the other side, Cel exhibited an endothermic peak at 275.87°C which 
is well matched with its reported melting point range of 280–282°C. 
Ed-CH-5-FU-Cel-MSs presented a depressed and relatively broad 
endothermic peak at 90.90°C which corroborated amorphization of the 
crystal structure of the drugs [34].
PXRD studies
PXRD studies were carried out to determine the crystalline nature 
of the drugs under investigation. The XRD diffractograms (Fig. 2) of 
5-FU and Cel exhibited the sharp and intense peaks, indicating the 
crystalline structure. While the diffractograms of Ed-CH-5-FU-Cel-MSs 
demonstrated, low intensity peaks designated to the amorphous lattice. 
This was consistent with the previous reports [33].
Particle size analysis and surface morphology
It is apparent from the results obtained from laser diffractometry, 
the mean particle size of Ed-CH-5-FU-Cel-MSs was found to be 
4.8±1.1µm and 2.7±0.9µm, respectively, for MSs prepared by emulsion 





Cel 3331 N-H stretching
1345 and 1138 S=O stretching
5-FU-Cel-PM 1345 and 1147 S=O stretching
1226 C-X
Ed-CH-5-FU-Cel-PM 1345 S=O stretching
1227 C-X




FTIR: Fourier transform infrared spectroscopy, 5-FU: 5-Fluorouracil, 
Cel: Celecoxib, CH: Chitosan, MSs: Microspheres, PM: Physical mixture
Fig. 1: Differential scanning calorimetry of (a) 5‑FU‑Cel‑PM and 
(b) Ed‑CH‑5‑FU‑Cel‑MSs estimated between 30°C and 300°C. Each 
sample under investigation was scanned thrice, and the average of 
it was considered. 5‑FU: 5‑Fluorouracil, Cel: Celecoxib, CH: Chitosan, 
MSs: Microspheres, PM: Physical mixture, Ed: Eudragit S 100
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polymerization method and nonaqueous solvent evaporation method 
with an insignificant difference (Unpaired t-test, p>0.05). The 
photomicrographs obtained from TEM indicated the spherical and 
uniform shape of the coated MSs without any distortion of surface 
texture (Fig. 3).
Drug EE and drug loading capacity
The results of drug EE and drug loading capacity of the Ed-CH-5-FU-
Cel-MSs are expressed in Table 2. The drug EE for MSs developed by 
emulsion polymerization method was calculated to be 71.30±2.3% 
and 35.20±1.9% with significant difference (Unpaired t-test, p>0.05) 
whereas the drug loading capacity was found to be in the range of 
6.5 mg/10 mg and 2.3 mg/10 mg for 5-FU and Cel, respectively. On 
the other hand, in case of MSs developed by nonaqueous solvent 
evaporation method, slight decrease in drug EE as well as in drug 
loading capacity was observed.
Each experiment was carried out in triplicate (n=3)
In vitro drug release studies
The formulation approach used in the development of Ed-CH-5-FU-
Cel-MSs was to delay the release of the combination of drugs in the 
stomach and to get a controlled drug release for a relatively long 
duration, especially at the site of action, i.e., colon. Results obtained 
from in vitro drug release study met with the expected outcome. 
Dissolution study was carried out in pH progression medium at 
37±0.5°C. It is evident from the drug release study that at 0.5 h, 
97.5±1.1 % 5-FU was released as compared (two-way ANOVA test, 
p<0.01) to 15.3±0.8% release of Cel from 5-FU-Cel-PM. Ed-CH-5-FU-
Cel-MSs exhibited the release of 92.1±2.9% of 5-FU in 8 h as compared 
(two-way ANOVA test, p<0.01) to 18.9±0.7 release of Cel after the 
same duration of time (Fig. 4).
Ed-CH-5-FU-Cel-MSs showed that there was no substantial amount 
of drug release (5-FU and Cel) in the initial 2 h in simulated gastric 
fluid (pH 1.2). The release of both drugs under investigation started in 
intestinal pH and the maximum release observed in the colonic milieu, 
the site of action.
In vitro cytotoxicity assay
To investigate the synergistic effect of 5-FU and Cel combination in 
CRC, the standard cell proliferation assay was performed on pure 
drugs as well as on the developed formulations. Cytotoxicity of 
the 5-FU, Cel, 5-FU-Cel-PM, Ed-CH-5-FU-Cel-MSs, and Bl-MSs was 
studied against HT-29 cell line and expressed in terms of percentage 
cell viability (Fig. 5). The drug-loaded MSs exhibited appreciable 
potency against HT-29 cells with an IC50 value of 35.9±4.2 µM, which 
is notably lower than (One-way ANOVA test, p˂0.05) IC50 value of pure 
Cel (48.7±2.1 µM), 5-FU (45.4±3.6 µM), and the combination of both 
drugs (47.3±2.5 µM). Bl-MSs did not produce any cytotoxicity against 
HT-29 cells. The results exhibited the possible synergistic effect when 
Cel and 5-FU were used in combination. This strategy could be used 
as a potential approach for the management of CRC due to controlled 
release phenomena [35,36].
CONCLUSION
In the present study, we have offered the oral drug delivery system in 
the form of MSs of 5-FU and Cel combination for the management of 
CRC. Carbohydrate polymer, CH was employed for the fabrication of MSs 
to enable the drug release in the colonic milieu. In addition, Ed coating 
has supported the tailored system to release the drug at the target site.
Our Eudragit coated carbohydrate based polymeric MSs of 5-FU and 
Cel combination will potentially improve the drug delivery in the colon 
while maintaining the high stability in the stomach and small intestine.
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Fig. 2: Powder X‑ray diffraction pattern of (a) 5‑FU; (b) Cel, and 
(c) Ed‑CH‑5‑FU‑Cel‑MSs measured between 10° and 60° at 2θ 
angle. Each sample was scanned thrice, and the average of that 
sample was considered. 5‑FU: 5‑Fluorouracil, Cel: Celecoxib, 
CH: Chitosan, MSs: Microspheres, Ed: Eudragit S 100
Table 2: Particle size, EE, and drug loading capacity of the drug‑loaded MSs (Ed‑CH‑5‑FU‑Cel‑MSs)
Parameter Emulsion polymerization method Nonaqueous solvent evaporation method
Particle size 4.8±1.1 µm 2.7±0.9 µm
EE 71.30±2.3% (5-FU) 70±1.7% (5-FU)
3 5.20±1.9% (Cel) 34.64±1.5% (Cel)
Drug loading capacity 6.5 mg/10 mg (5-FU) 6.4 mg/10 mg (5-FU)
2.3 mg/10 mg (Cel) 2.32 mg/10 mg (Cel)
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